<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03726242</url>
  </required_header>
  <id_info>
    <org_study_id>Levcromakalim local injection</org_study_id>
    <nct_id>NCT03726242</nct_id>
  </id_info>
  <brief_title>Peripheral Nociceptive Effects of Levcromakalim</brief_title>
  <official_title>Study of Local Physiological Effects Following Intradermal and Intramuscular Injection of Levcromacalim</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intradermal and intramuscular injection of levcromacalim and placebo (sterile saline) on the
      forehead and forearm of healthy subjects and the following will be investigated:

        1. Prevalence and intensity of pain

        2. Prevalence and intensity of itching

        3. Occurrence and intensity of local redness and swelling

        4. Occurrence and intensity of local changes in skin temperature and blood flow
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">January 20, 2019</completion_date>
  <primary_completion_date type="Actual">January 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Parallel, randomized placebo controlled and crossover study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence and change of pain from baseline</measure>
    <time_frame>Before and after injection of levcromakalim compared with before and after injection of saline. Time of measurements is baseline, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min and 45 min after the injection</time_frame>
    <description>Occurrence and intensity of pain after levcromakalim injektion compared to placebo. To measure pain numerical rating scale (NRS) 0-10 will be used.
The outcome measure is pain and the unit that will be used to measure the pain is NRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence and change of Itching from baseline</measure>
    <time_frame>Before and after injection of levcromakalim compared with before and after injection of saline. Time of measurements is baseline, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min and 45 min after the injection</time_frame>
    <description>Occurrence and intensity of Itching after levcromakalim injektion compared to placebo. To measure itching numerical rating scale (NRS) 0-10 will be used.
The outcome measure is itching and the unit that will be used to measure the itching is NRS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and change of redness from baseline</measure>
    <time_frame>Before and after injection of levcromakalim compared with before and after injection of saline. Time of measurements is baseline, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min and 45 min after the injection.</time_frame>
    <description>Occurrence and change of redness after levcromakalim injektion compared to placebo. The areal of the redness will be measured.
The outcome measure is redness and the unit that will be used to measure the redness is areal cm^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and change of swelling from baseline</measure>
    <time_frame>Before and after injection of levcromakalim compared with before and after injection of saline. Time of measurements is baseline, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min and 45 min after the injection.</time_frame>
    <description>Occurrence and change of swelling after levcromakalim injektion compared to placebo. The areal of the swelling will be measured.
The outcome measure is swelling and the unit that will be used to measure the swelling is areal cm^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood flow from baseline</measure>
    <time_frame>Before and after injection of levcromakalim compared with before and after injection of saline. Time of measurements is baseline, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min and 45 min after the injection.</time_frame>
    <description>Change of blodflow after levcromakalim injektion compared to placebo. The intensity of the blodd flow will be measured by laser speckle The outcome measure is change of blood flow and the laser speckle will be used to measure the blood flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of skin temperature from baseline</measure>
    <time_frame>Before and after injection of levcromakalim compared with before and after injection of saline. Time of measurements is baseline, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min and 45 min after the injection.</time_frame>
    <description>Change of skin temperature after levcromakalim injektion compared to placebo. The temperature will be measured by thermovision camera.
The outcome measure is the change of skin temperature and the thermovision camera will be used to measure skin temperature.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pain</condition>
  <condition>Levcromakalim</condition>
  <arm_group>
    <arm_group_label>Levcromakalim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levcromakalim</intervention_name>
    <description>To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.</description>
    <arm_group_label>Levcromakalim</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.</description>
    <arm_group_label>Levcromakalim</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers of both sexes.

          2. 18-60 years.

          3. 50-100 kg.

          4. Women of childbearing potential must use adequate contraception.

        Exclusion Criteria:

          1. A history of serious somatic disease

          2. Migraine or any other type of headache (except episodic tension-type headache less
             than once a month)

          3. Daily intake of any medication except contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish headache center</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>January 20, 2019</last_update_submitted>
  <last_update_submitted_qc>January 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Mahdi Al-Karagholi</investigator_full_name>
    <investigator_title>MD, PhD student, Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cromakalim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

